Patent application number | Description | Published |
20080300166 | Treatment of Melanoma with Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 12-04-2008 |
20090074815 | Immunomodulator Compounds as Vaccine Enhancers - A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine. | 03-19-2009 |
20090088392 | TREATMENT OF MELANOMA - An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject. | 04-02-2009 |
20090143313 | Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds - An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection. | 06-04-2009 |
20100016211 | Treatment of Melanoma With Alpha Thymosin Peptides - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 01-21-2010 |
20100197595 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 08-05-2010 |
20100221274 | METHOD OF ADMINISTERING A THYMOSIN ALPHA 1 PEPTIDE - A Thymosin alpha 1 (TA1) peptide is administered to a patient in need of immune stimulation so as to substantially continuously maintain an immune stimulating-effective amount of the TA1 peptide in the patient. The administration method may be by continuous infusion. | 09-02-2010 |
20100267637 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor. | 10-21-2010 |
20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS - The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen. | 11-11-2010 |
20100317583 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH AN ANTINEOPLASTIC HEAT SHOCK APOPTOSIS ACTIVATOR (HSAA) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents. | 12-16-2010 |
20100330093 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH ANTIBODIES AGAINST CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4). | 12-30-2010 |
20110189305 | TREATMENT OF LUNG CANCER - An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce lung cancer in a subject. | 08-04-2011 |
20110200558 | Treatment or Prevention of Hepatitis C with Immunomodulator Compounds - A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an effective amount of an immunomodulator compound of Formula A | 08-18-2011 |
20130296223 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS - The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock. | 11-07-2013 |
20140213506 | THYMOSIN ALPHA PEPTIDE FOR PREVENTING, REDUCING THE SEVERITY OF, AND TREATING INFECTION - The present invention provides methods for preventing, treating, or reducing the severity of infection, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen, so as to prime or enhance a patient's immune response for pathogen exposure. In certain embodiments, the alpha thymosin regimen is scheduled or timed with respect to potential or expected pathogen exposures. The regimen of alpha thymosin peptide as described herein provides the patient with a more robust immune response to pathogen exposure, including higher antibody titers and/or a more rapid antibody response. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of nosocomial infection or illness. | 07-31-2014 |
20150024994 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS - The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunocompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock. | 01-22-2015 |